Promoted Companies
SORT BY:
PharmaCyte Biotech (pmcb)
| Total paid for Promotions this month: | $0 | ||
| E-mails this Month: | 1 | ||
| Estimated Volume Generated: | $0 | ||
| Research Report on pmcb: | Click to see | ||
| * The information presented is based on information for Jun , 2016 | |||
PMCB_--_PharmaCyte_Biotech_CEO_Interviews_with_SCN_at_NASDAQ Jun 29, 2016 09:00
PharmaCyte CEO Interviews with Small Cap Nation at NASDAQ.
View this email in your browser
PharmaCyte Biotech CEO Interviews at NASDAQ with Small Cap Nation & Analyst Kevin Baker of Baker Research Group
In the 2 videos below PharmaCyte Biotech's (OTCQB: PMCB) CEO Kenneth Waggoner discusses the company’s upcoming Phase 2b clinical trial in advanced pancreatic
...read more
| Promoter: | Stock Market Media Group | Paying Party: | No Third Party |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| PMCB | No compensation | UNKNOWN |
| Max Profit: 15.46 % | Gain at close: Pending |
PMCB_--_Valuing_PharmaCyte_Biotech's Mar 10, 2016 08:29
Valuing PharmaCyte Biotech's New Treatment Option for Pancreatic Cancer
Is this email not displaying correctly? View it in your browser.
Valuing PharmaCyte Biotech's New Treatment Option for Pancreatic Cancer
As PharmaCyte Biotech (OTCQB – PMCB - $0.0625) moves closer to its clinical trial in pancreatic cancer, we will be bringing our subscribers
...read more
| Promoter: | Stock Market Media Group | Paying Party: | No Third Party |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| PMCB | No compensation | UNKNOWN |
| Max Profit: 5.43 % | Gain at close: Pending |
The Guide and PMCB Nov 30, 2015 08:45
Good morning!
Hope everyone had an enjoyable Thanksgiving weekend. Which sectors will be on fire in the weeks ahead? Is the small cap segment about to break out? The four themes in this week’s Guide include:
⇒ See which sectors could produce the best returns, moderate returns, and which ones to avoid ⇒ Why small stocks are about to break out and are set to bust through the closing
...read more
| Promoter: | Goldman Small Cap Research | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| PMCB | $22,000 | UNKNOWN |
| Max Profit: 21.93 % | Gain at close: Pending |
Cancer Treatment Approval Odds and Timing Just Moved Much Higher Oct 26, 2015 08:12
Good morning!
Last week was an incredible week for PharmaCyte Biotech (OTC – PMCB), which prompted us to issue a new research update. Major industry and company news released last week should take investor sentiment and the stock to a new level regarding the potential and timing of FDA approval for PharmaCyte’s pancreatic cancer treatment for patients with locally advanced pancreatic cancer.
Pancreatic
...read more
| Promoter: | Goldman Small Cap Research | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| PMCB | $22,000 | UNKNOWN |
| Max Profit: 21.93 % | Gain at close: Pending |
OTCJ : PharmaCyte (PMCB): FDA Trials Imminent Designed and Imminent Oct 22, 2015 08:57
October 22, 2015
Volume XVIII, Issue 52
OTC Journal Newsletter
PharmaCyte (PMCB): Moving To FDA Trials
Soon To Be Moving Up The Charts
Most people don't quite get the distinction, but moving from Studies to Trials is a very big deal for a Biotech company. In fact, the move to formal Trials from Studies allows Wall Street to place a much higher value on a company's
...read more
| Promoter: | OTCJournal | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| PMCB | $14,000 | UNKNOWN |
| Max Profit: 0.66 % | Gain at close: Pending |
OTCJ : Revolutionary Diabetes Treatment Oct 16, 2015 08:39
October 16, 2015
Volume XVIII, Issue 49
OTC Journal Newsletter
PharmaCyte (PMCB) Diabetes Treatment at Forefront of Medical Breakthrough
I've just finished reading 13 current articles highighting a potential cure for Type 1 Diabetes- also known as Juvenile Diabetes. It's a disease you have for life, but Type 1 manifests in children- hence the term "Juvenile." Type
...read more
| Promoter: | OTCJournal | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| PMCB | $14,000 | UNKNOWN |
| Max Profit: 0.66 % | Gain at close: Pending |
OTCJ : Pharmacyte Comeback; Bear Killer October Oct 11, 2015 15:41
October 10, 2015
Volume XVIII, Issue 47
OTC Journal Newsletter
October- The Bear Killer
We are finally through September- seasonally the worst month of the year for stocks, and ofttimes a rough time for small stocks.
This year the volatility was particularly ugly with lots of Global turmoil, Fed controversy, China imploding, and markets melting down.
Naturally, it's
...read more
| Promoter: | OTCJournal | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| PMCB | $14,000 | UNKNOWN |
| Max Profit: 0.66 % | Gain at close: Pending |
Undervalued_PharmaCyte Oct 08, 2015 08:15
Good morning!
PharmaCyte Biotech (OTC – PMCB) may be undervalued today but that is not likely to last. Here are 3 reasons why it could quickly return to its highs of six months ago.
Phase 2B Pancreatic Cancer Trial Launch Is Only Months Away
PMCB is in the middle/late innings of its preparation to initiate a highly anticipated multi-site Phase 2b clinical trial in 1Q16,
...read more
| Promoter: | Goldman Small Cap Research | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| PMCB | $22,000 | UNKNOWN |
| Max Profit: 21.93 % | Gain at close: Pending |
If Only Steve Jobs Had Known PharmaCyte Biotech & Cell-in-a-Box Sep 17, 2015 09:01
Date: September 17, 2015
If Only Steve Jobs Had Known PharmaCyte Biotech & Cell-in-a-Box
Symbol: PMCB
If Only Steve Jobs Had Known PharmaCyte Biotech & Cell-in-a-Box
SAN DIEGO, CA -- September 17, 2015 -- InvestorsHub NewsWire -- If only Steve Jobs had access to this therapy before Pancreatic Cancer took his life. Had he known of PharmaCyte Biotech's (OTCQB: PMCB) signature
...read more
| Promoter: | InvestorsHub News | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| PMCB | $19,000 | UNKNOWN |
| Max Profit: 2.27 % | Gain at close: Pending |
PMCB_-_New_Drug_application Sep 16, 2015 08:53
Good Morning,
Not sure how I missed this news but in the upcoming days this biotech company could very well be the talk of Wall Street !
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech Discusses Major Milestones Ahead of Phase 2b Clinical Trial in Pancreatic Cancer
The trial will test the effectiveness and safety of PharmaCyte Biotech’s pancreatic cancer treatment. This
...read more
| Promoter: | ThePennyStockHero | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| PMCB | $2,000 | UNKNOWN |
| Max Profit: 0.50 % | Gain at close: Pending |